Skip to main content

Table 2 Univariate and multivariable analyses for the risk of major bleeding

From: Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study

  Univariate analysis Multivariable analysis
Crude OR
(95% CI)
P-value Adjusted OR
(95% CI)
P-value
Age (per 1 year) 1.03 (1.01–1.05)  < 0.001 1.01 (0.99–1.04) 0.17
Men 0.66 (0.37–1.20) 0.17 1.20 (0.63–2.29) 0.58
History of major bleeding 12.8 (4.66–35.7)  < 0.001 10.8 (3.16–36.6)  < 0.001
Severity of COVID-19 at admission
 Mild (Reference)  
 Moderate 5.02 (2.22–11.4)  < 0.001 1.98 (0.77–5.13) 0.16
 Severe 30.2 (13.6–67.1)  < 0.001 6.15 (2.24–16.9) 0.001
Pharmacological thromboprophylaxis
 No anticoagulants (Reference)  
 Prophylactic dose (LMWH or UFH) 6.30 (2.52–15.8)  < 0.001 3.02 (1.04–8.82) 0.04
 Therapeutic dose (Warfarin or DOAC) 7.69 (2.32–25.5)  < 0.001 3.17 (0.84–12.0) 0.09
 Therapeutic dose (UFH) 52.7 (21.3–130.3)  < 0.001 13.7 (4.27–44.2)  < 0.001
  1. Age, sex, history of major bleeding, severity of COVID-19 at admission, and pharmacological thromboprophylaxis were included in the multivariate analysis
  2. OR Odds ratio, CI Confidence interval, COVID-19 Coronavirus disease 2019, LMWH Low molecular weight heparin, UFH Unfractionated heparin, DOAC Direct oral anticoagulant, vs Versus